Quantitative CT in AATD linked airway wall thickening and bronchiectasis to lung function, while wall thickness best ...
Rising prevalence of genetic respiratory disorders, expanding healthcare infrastructure, and strong R&D investments fuel sustained market growth worldwide.Austin, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) ...
Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.
Investor's Business Daily on MSN
Beam soars 22% as FDA signs off on its ambitious gene-editing plan
Beam stock launched Monday after the company reached a deal with the Food and Drug Administration for its gene-editing drug, ...
The firm expects its $1.25 billion cash runway to cover operating and capital expenses through 2029, including development plans for key assets.
Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has cleared its ...
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on ...
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency ...
Alpha-1 antitrypsin deficiency (AATD) leaves lungs vulnerable to damage. Dr. Malik Khurram Khan, who leads UK's advanced COPD clinic, wants to see more people screened for the condition. UK Healthcare ...
Objective: To evaluate the prevalence of alpha-1 antitrypsin (AAT) variants through SERPINA1 genotyping in patients with non-cystic fibrosis bronchiectasis, and assess their clinical, functional and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results